Bioresorbable vascular stents and drug-eluting stents in treatment of coronary heart disease: a meta-analysis
Open Access
- 28 January 2020
- journal article
- research article
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 15 (1) , 1-7
Abstract
Objective: To compare the efficacy and safety of bioresorbable vascular stents (BVS) and drug-eluting stents (DES) in coronary heart disease. Methods: The full text of clinical studies involving BVS and DES was retrieved in PubMed, Springer, EMBASE, Wiley-Blackwell, and Chinese Journal Full-text Database. Review Manager 5.3 was used for meta-analysis to evaluate the risk of target lesion failure, stent thrombosis and cardiac death in BVS and DES. Results: Finally, 10 studies with 6383 patients were included in the meta-analysis. Compared with DES group, BVS group had significantly increased risk of target lesion failure (OR = 1.46, 95%CI 1.20–1.79, P = 0.0002; P Heterogeneity = 0.68, I2 = 0%), stent thrombosis (OR = 2.70, 95%CI 1.57–4.66, P = 0.0003; P Heterogeneity = 1.00, I2 = 0%) and cardiac death (OR = 2.19, 95%CI 1.17–4.07, P = 0.01; P Heterogeneity = 0.93, I2 = 0%). Conclusion: This study shows that DES is a safer treatment than BVS for coronary revascularization.Keywords
This publication has 27 references indexed in Scilit:
- A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB JapanEuropean Heart Journal, 2015
- Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With Everolimus-Eluting Bioresorbable Vascular ScaffoldsJACC, 2015
- A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trialThe Lancet, 2015
- Incidence and Imaging Outcomes of Acute Scaffold Disruption and Late Structural Discontinuity After Implantation of the Absorb Everolimus-Eluting Fully Bioresorbable Vascular ScaffoldJACC: Cardiovascular Interventions, 2014
- Current Status of Bioresorbable Scaffolds in the Treatment of Coronary Artery DiseaseJACC, 2014
- Complex coronary artery bifurcation treatment utilizing everolimus-eluting bioresorbable vascular scaffolds and optical coherence tomographyCoronary Artery Disease, 2014
- Current and Future Perspectives On drug-eluting Bioresorbable Coronary ScaffoldsFuture Cardiology, 2014
- Bioresorbable scaffolds in the treatment of coronary artery diseaseMedical Devices: Evidence and Research, 2013
- Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trialEuroIntervention, 2012
- Analysis of 1 year virtual histology changes in coronary plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffoldThe International Journal of Cardiovascular Imaging, 2011